Andrew Hopkins, DPhil, CBE, FRS — CEO
Founder of Exscientia (NASDAQ: EXAI), Andrew Hopkins is a pioneer in AI-driven drug discovery, leading the development of the first AI-designed therapeutics to progress from concept to clinic. Under his leadership, Exscientia completed a $3.3 billion IPO, marking the largest IPO raise for any European biotech on NASDAQ. Recognized for his groundbreaking work at the intersection of AI and medicine, he was named to the inaugural TIME 100 AI list of most influential people and is a Prix Galien Award winner.